HK1202310A1 - 具有氨基酸骨架的單鏈核酸分子 - Google Patents

具有氨基酸骨架的單鏈核酸分子

Info

Publication number
HK1202310A1
HK1202310A1 HK15102793.8A HK15102793A HK1202310A1 HK 1202310 A1 HK1202310 A1 HK 1202310A1 HK 15102793 A HK15102793 A HK 15102793A HK 1202310 A1 HK1202310 A1 HK 1202310A1
Authority
HK
Hong Kong
Prior art keywords
stranded nucleic
amino acid
nucleic acid
acid molecule
backbone
Prior art date
Application number
HK15102793.8A
Other languages
English (en)
Inventor
Ohgi Tadaaki
Suzuki Hiroshi
Hamasaki Tomohiro
Aoki Eriko
Original Assignee
Bonac Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bonac Corp filed Critical Bonac Corp
Publication of HK1202310A1 publication Critical patent/HK1202310A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/04—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
    • C07C225/06—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and acyclic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/533—Physical structure partially self-complementary or closed having a mismatch or nick in at least one of the strands
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK15102793.8A 2012-01-07 2015-03-18 具有氨基酸骨架的單鏈核酸分子 HK1202310A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012001711 2012-01-07
JP2012026745 2012-02-09
PCT/JP2012/084247 WO2013103146A1 (ja) 2012-01-07 2012-12-29 アミノ酸骨格を有する一本鎖核酸分子

Publications (1)

Publication Number Publication Date
HK1202310A1 true HK1202310A1 (zh) 2015-09-25

Family

ID=48745204

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102793.8A HK1202310A1 (zh) 2012-01-07 2015-03-18 具有氨基酸骨架的單鏈核酸分子

Country Status (8)

Country Link
US (1) US9528111B2 (zh)
EP (1) EP2801617B1 (zh)
JP (1) JP5876890B2 (zh)
KR (1) KR101674778B1 (zh)
CN (2) CN104039961A (zh)
ES (1) ES2645996T3 (zh)
HK (1) HK1202310A1 (zh)
WO (1) WO2013103146A1 (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2824184B1 (en) * 2012-03-04 2017-09-27 Bonac Corporation micro-RNA INHIBITOR
WO2013180038A1 (ja) 2012-05-26 2013-12-05 株式会社ボナック デリバリー機能を有する遺伝子発現制御用の一本鎖核酸分子
JP6486836B2 (ja) 2013-12-26 2019-03-20 学校法人東京医科大学 遺伝子発現制御のための人工ミミックｍｉＲＮＡおよびその用途
JP6492014B2 (ja) * 2013-12-27 2019-03-27 株式会社ボナック 遺伝子発現制御のための人工マッチ型ｍｉＲＮＡおよびその用途
CN112646812A (zh) * 2013-12-27 2021-04-13 株式会社博纳克 控制基因表达的人工匹配型miRNA及其用途
US11027023B2 (en) 2014-12-27 2021-06-08 Bonac Corporation Natural type miRNA for controlling gene expression, and use of same
WO2016158809A1 (ja) * 2015-03-27 2016-10-06 株式会社ボナック デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子
KR102099711B1 (ko) 2015-10-30 2020-04-14 가부시키가이샤 보낙 TGF-β1 유전자의 발현을 억제하는 단일-가닥 핵산 분자를 안정적으로 함유하는 조성물
BR112018015164A2 (pt) 2016-01-26 2018-12-26 Nissan Chemical Corp oligonucleotídeo de fita simples
AU2017213405B2 (en) * 2016-01-30 2021-02-04 Bonac Corporation Artificial single guide RNA and use thereof
EP3584319A4 (en) * 2017-02-06 2021-04-14 Nissan Chemical Corporation SINGLE-STRAND OLIGONUCLEOTIDE
WO2018182008A1 (ja) 2017-03-31 2018-10-04 株式会社ボナック 遺伝子発現制御機能を有する環状型核酸分子
EA202090393A1 (ru) 2017-07-28 2020-05-20 Кёрин Фармасьютикал Ко., Лтд. Терапевтическое средство от фиброза
EP3696269A4 (en) * 2017-10-13 2021-09-01 Bonac Corporation SINGLE STRAND NUCLEIC ACID MOLECULE AND ITS PRODUCTION PROCESS
TWI830718B (zh) 2018-02-09 2024-02-01 日商住友化學股份有限公司 核酸分子之製造方法
CA3094303A1 (en) 2018-03-20 2019-09-26 Tokyo Institute Of Technology Antisense oligonucleotide reduced in toxicity
JP6631751B1 (ja) 2018-03-30 2020-01-15 東レ株式会社 ヘアピン型一本鎖ｒｎａ分子の製造方法
JP6817493B2 (ja) * 2018-03-30 2021-01-20 住友化学株式会社 一本鎖ｒｎａの製造方法
EP3862431B1 (en) 2018-10-02 2024-06-26 Toray Industries, Inc. Method for producing hairpin single-strand rna molecules
WO2020202953A1 (ja) 2019-03-29 2020-10-08 住友化学株式会社 無機多孔質担体、及びこれを用いた核酸の製造方法
WO2020202951A1 (ja) 2019-03-29 2020-10-08 住友化学株式会社 無機多孔質担体、及びこれを用いた核酸の製造方法
EP3950126A4 (en) 2019-03-29 2023-11-01 Sumitomo Chemical Company Limited INORGANIC POROUS SUPPORT AND METHOD FOR PRODUCING NUCLEIC ACIDS THEREFROM
WO2020202952A1 (ja) 2019-03-29 2020-10-08 住友化学株式会社 無機多孔質担体、及びこれを用いた核酸の製造方法
JPWO2020202949A1 (zh) 2019-03-29 2020-10-08
US20230167152A1 (en) * 2020-03-27 2023-06-01 Sumitomo Chemical Company, Limited Method for producing nucleic acid oligomer
US20230256425A1 (en) 2020-05-13 2023-08-17 Sumitomo Chemical Company, Limited Inorganic porous substrate, inorganic porous support, and nucleic acid production method
US20230357767A1 (en) * 2020-08-25 2023-11-09 Bonac Corporation Novel nucleic acid molecule inhibiting expression of target gene
WO2022064908A1 (ja) 2020-09-24 2022-03-31 住友化学株式会社 核酸オリゴマーの製造方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE873543C (de) 1942-10-28 1953-04-16 Basf Ag Verfahren zur Herstellung von hydroxyl- bzw. sulfhydryl-gruppenhaltigen Dicarbaminsaeureestern
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4550163A (en) 1979-02-05 1985-10-29 Abbott Laboratories Ligand analog-irreversible enzyme inhibitor conjugates
US20030232355A1 (en) * 1992-05-22 2003-12-18 Isis Pharmaceuticals, Inc. Double-stranded peptide nucleic acids
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
US6852334B1 (en) * 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
TWI321054B (en) 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
JP4408628B2 (ja) 2001-03-09 2010-02-03 ボストン プローブス，インコーポレイテッド 組み合わせオリゴマーならびにそれらの調製のためのライブラリーに適する、方法、キット、および組成物
ATE348104T1 (de) 2001-10-29 2007-01-15 Univ Mcgill Azyklische linker enthaltende oligonukleotide und deren verwendungen
US20040058886A1 (en) 2002-08-08 2004-03-25 Dharmacon, Inc. Short interfering RNAs having a hairpin structure containing a non-nucleotide loop
WO2004111072A2 (en) * 2003-06-12 2004-12-23 Applera Corporation Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same
WO2005030960A1 (ja) * 2003-09-30 2005-04-07 Anges Mg, Inc. ステイプル型オリゴヌクレオチドおよびそれからなる医薬
MX2007008065A (es) * 2004-12-30 2008-03-04 Todd M Hauser Composiciones y metodos para modular la expresion genica usando oligonucleotidos autoprotegidos.
US20100317714A1 (en) 2007-11-29 2010-12-16 Suzhou Ribo Life Science Co., Ltd Complex molecule interfering the expression of target genes and its preparing methods
WO2009076321A2 (en) 2007-12-07 2009-06-18 Halo-Bio Rnai Therapeutics Inc. Compositions and methods for modulating gene expression using asymmetrically-active precursor polynucleotides
CA2768598A1 (en) * 2009-07-22 2011-01-27 Cenix Bioscience Gmbh Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes

Also Published As

Publication number Publication date
KR20140111688A (ko) 2014-09-19
JP5876890B2 (ja) 2016-03-02
WO2013103146A1 (ja) 2013-07-11
US9528111B2 (en) 2016-12-27
EP2801617A1 (en) 2014-11-12
CN110055247A (zh) 2019-07-26
EP2801617A4 (en) 2015-09-30
US20140329886A1 (en) 2014-11-06
ES2645996T3 (es) 2017-12-11
JPWO2013103146A1 (ja) 2015-05-11
CN104039961A (zh) 2014-09-10
KR101674778B1 (ko) 2016-11-09
EP2801617B1 (en) 2017-09-06

Similar Documents

Publication Publication Date Title
HK1202310A1 (zh) 具有氨基酸骨架的單鏈核酸分子
HK1244509A1 (zh) 包含鎖核酸基序的基於寡核苷酸的抑制劑
HK1209162A1 (zh) 條形編碼核酸
EP2917372A4 (en) NUCLEIC ACID SEQUENCING USING LABELS
IL231983A0 (en) Dna containing tricyclo-phosphorothioate
SG11201405542UA (en) Artificial nucleic acid molecules
EP2799548A4 (en) ANTISENSE NUCLEIC ACID
GB201204407D0 (en) Nucleic acid molecule
HUE056246T2 (hu) Készítmények nukleinsav-szekvenáláshoz
EP2729182A4 (en) NUCLEIC COMPLEX
ZA201205891B (en) Dna polymerases
EP2694683A4 (en) CONFORMATIONALLY PRE-ORGANIZED MINIPEG-CONTAINING GAMMA PEPTIDE NUCLEIC ACIDS
EP2705162A4 (en) METHOD FOR DETECTING NUCLEIC ACID SEQUENCE VARIANTS
EP2691522A4 (en) FUNCTIONAL NUCLEIC ACID MOLECULE AND APPLICATIONS THEREOF
HK1216653A1 (zh) 多重核酸檢測方法
EP2764112A4 (en) DIRECT NUCLEIC ACID ANALYSIS
GB201118636D0 (en) Nucleotide sequence
GB2503856B (en) Methods for nucleic acid purification
EP2902488A4 (en) MODIFIED DNA POLYMERASE
HK1245104A1 (zh) Dna疫苗
EP2798092A4 (en) nucleic acid hybridization probes
EP2700414A4 (en) SELF-GELATINABLE NUCLEIC ACID
EP2844772A4 (en) DNA SEQUENCING
EP2682462A4 (en) (Nucleic acid) polysaccharide COMPLEX
EP2702065A4 (en) DNA EXTRACTION IN TARGET MOLECULE PURIFICATION

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20221225